https://www.fresenius.com en-us Thu, 12 Nov 2026 14:45:00 +0100 Thu, 12 Nov 2026 14:45:00 +0100 Thu, 12 Nov 2026 14:45:00 +0100 <![CDATA[Fresenius completes sale of 13.4 million Fresenius Medical Care shares at €39.00 per share, raising approximately €524 million]]> Thu, 12 Nov 2026 01:30:30 +0100 <![CDATA[Fresenius announces intention to sell approximately 13.4 million shares in Fresenius Medical Care AG,]]> Wed, 04 Nov 2026 13:45:00 +0100 <![CDATA[Fresenius delivers an excellent quarter and is scaling its Growth Vectors - Core EPS guidance improved]]> Mon, 02 Nov 2026 14:00:00 +0100 <![CDATA[Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline ]]> Fri, 16 Oct 2026 00:00:00 +0200 <![CDATA[Supervisory Board appoints Dr. Marc-Alexander Mahl to the Fresenius Management Board and extends Sara Hennicken’s contract]]> Tue, 13 Oct 2026 19:24:56 +0200 <![CDATA[Q3 2026 Aide Memoire available]]> overview section.As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q3 2026 financial results will be published on November 4, 2026.]]> Thu, 01 Oct 2026 13:00:00 +0200 <![CDATA[Fresenius acquires remaining 45% of mAbxience for up to €750 million, taking full ownership of its biosimilars platform]]> Fri, 25 Sep 2026 15:45:00 +0200 <![CDATA[Fresenius expands European production capacity to enhance healthcare supply chain resilience]]> Wed, 16 Sep 2026 15:44:55 +0200 <![CDATA[DRG inflator 2027 expected at 4.85%]]> Wed, 09 Sep 2026 19:31:49 +0200 <![CDATA[Fresenius reorganizes its hospital services business]]> Mon, 07 Sep 2026 12:45:00 +0200 <![CDATA[Fresenius expands Medical Nutrition Portfolio with new real-food-based enteral nutrition concept]]> Fri, 21 Aug 2026 00:00:00 +0200 <![CDATA[Fresenius raises approximately €300 million through sale of 7.8 million Fresenius Medical Care shares]]> Mon, 10 Aug 2026 19:34:21 +0200 <![CDATA[Fitch Ratings upgrades outlook for Fresenius SE from stable to positive]]> Thu, 06 Aug 2026 19:00:00 +0200 <![CDATA[Fresenius transitions to registered shares – automatic conversion for shareholders]]> Wed, 05 Aug 2026 04:01:00 +0200 <![CDATA[#FutureFresenius: Excellent Q2 performance demonstrates structural step-up – Guidance raised]]> Mon, 03 Aug 2026 14:30:00 +0200 <![CDATA[Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market]]> Fri, 31 Jul 2026 14:19:54 +0200 <![CDATA[Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate]]> Thu, 23 Jul 2026 16:00:00 +0200 <![CDATA[Fresenius establishes venture fund of more than €200 million to drive healthcare innovation]]> Wed, 15 Jul 2026 16:14:29 +0200 <![CDATA[Q2 2026 Aide Memoire available]]> financial results section.As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q2 2026 financial results will be published on August 5, 2026.]]> Mon, 13 Jul 2026 13:00:00 +0200 <![CDATA[GKV Stabilization Act approved]]>